Maravai Lifesciences Holdings Inc (MRVI) - Total Assets
Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) holds total assets worth $849.19 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Maravai Lifesciences Holdings Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Maravai Lifesciences Holdings Inc - Total Assets Trend (2018–2024)
This chart illustrates how Maravai Lifesciences Holdings Inc's total assets have evolved over time, based on quarterly financial data. See MRVI total equity for net asset value and shareholders' equity analysis.
Maravai Lifesciences Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Maravai Lifesciences Holdings Inc's total assets of $849.19 Million consist of 42.6% current assets and 57.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.0% |
| Accounts Receivable | $38.52 Million | 3.8% |
| Inventory | $50.08 Million | 5.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $194.96 Million | 19.3% |
| Goodwill | $159.88 Million | 15.9% |
Asset Composition Trend (2018–2024)
This chart illustrates how Maravai Lifesciences Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Maravai Lifesciences Holdings Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maravai Lifesciences Holdings Inc's current assets represent 42.6% of total assets in 2024, an increase from 10.0% in 2018.
- Cash Position: Cash and equivalents constituted 32.0% of total assets in 2024, up from 4.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, a decrease from 81.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 19.3% of total assets.
Maravai Lifesciences Holdings Inc Competitors by Total Assets
Key competitors of Maravai Lifesciences Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Maravai Lifesciences Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.29 | 10.74 | 2.54 |
| Quick Ratio | 4.56 | 9.94 | 2.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $264.29 Million | $615.86 Million | $200.82 Million |
Maravai Lifesciences Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Maravai Lifesciences Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.75 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -32.2% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $952.80 Million USD |
Valuation Analysis
Near Book Valuation: The market values Maravai Lifesciences Holdings Inc's assets close to their book value (0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Maravai Lifesciences Holdings Inc's assets decreased by 32.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Maravai Lifesciences Holdings Inc (2018–2024)
The table below shows the annual total assets of Maravai Lifesciences Holdings Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.01 Billion | -32.22% |
| 2023-12-31 | $1.49 Billion | -34.83% |
| 2022-12-31 | $2.28 Billion | +18.98% |
| 2021-12-31 | $1.92 Billion | +50.96% |
| 2020-12-31 | $1.27 Billion | +119.92% |
| 2019-12-31 | $577.80 Million | +7.06% |
| 2018-12-31 | $539.68 Million | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Producti… Read more